Hemorheological profiles and chronic inflammation markers in transfusion-dependent and non-transfusion- dependent thalassemia.
adhesion molecules
blood viscosity
chemokines
cytokines
endothelium
hemorheology
thalassemia intermedia
thalassemia major
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
11
2022
accepted:
19
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
The rheological properties of blood play an important role in regulating blood flow in micro and macro circulation. In thalassemia syndromes red blood cells exhibit altered hemodynamic properties that facilitate microcirculatory diseases: increased aggregation and reduced deformability, as well as a marked increase in adherence to the vascular endothelial cells. A personalized approach to treating thalassemia patients (transfusions, iron chelation, and splenectomy), has increased patients' life expectancy, however they generally present many complications and several studies have demonstrated the presence of high incidence of thromboembolic events. In this study the hemorheological profiles of thalassemia patients have been characterized to point out new indices of vascular impairment in thalassemia. Plasma viscosity, blood viscosities at low and high shear rates (η1 and η200, respectively), erythrocyte aggregation index (η1/η200), and the erythrocyte viscoelastic profile (elastic modulus G', and viscous modulus G") have been studied in transfusion-dependent and non-transfusion-dependent thalassemia patients. Moreover, the levels of inflammation biomarkers in thalassemia have been evaluated to investigate a relationship between the biomarkers, the disease severity and the rheological parameters. The biomarkers studied are the main components of the immune and endothelial systems or are related to vascular inflammation: cytokines (IL-2, IL-6, IL-10, IL-17A, TNF-alpha), chemokines (IL-8, MIP-1alpha), adipocytokines (leptin and adiponectin), growth factors (VEGF, angiopoietin-1), adhesion molecules (ICAM-1, VCAM-1, E-selectin, L-selectin), and a monocyte/macrophage activation marker (CD163). This study shows that transfusion-dependent thalassemia patients, both major and intermedia, have blood viscosities comparable to those of healthy subjects. Non-transfusion-dependent thalassemia intermedia patients show high blood viscosities at low shear rates (η1), corresponding to the flow conditions of the microcirculation, an increase in erythrocyte aggregation, and high values of the elastic G' and viscous G" modules that reflect a reduced erythrocyte deformability and an increase in blood viscosity. Levels of cytokines, chemokines and adhesion molecules are different in transfusion- and non-transfusion dependent patients and positive correlations between η1 or η1/η200 and the cytokines IL-6 and IL-10 have been observed. The evaluation of the hemorheological profiles in thalassemia can provide new indicators of vascular impairment and disease severity in thalassemia in order to prevent the onset of thromboembolic events.
Identifiants
pubmed: 36699704
doi: 10.3389/fmolb.2022.1108896
pii: 1108896
pmc: PMC9868635
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1108896Informations de copyright
Copyright © 2023 Caprari, Profumo, Massimi, Buttari, Riganò, Regine, Gabbianelli, Rossi, Risoluti, Materazzi, Gullifa, Maffei and Sorrentino.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood Coagul Fibrinolysis. 2012 Oct;23(7):640-8
pubmed: 22885767
Cytokine. 2006 Sep;35(5-6):253-7
pubmed: 17081768
Blood Coagul Fibrinolysis. 2008 Oct;19(7):611-4
pubmed: 18832899
Clin Hemorheol Microcirc. 2004;31(2):89-96
pubmed: 15310943
Blood Cells Mol Dis. 2015 Feb;54(2):170-6
pubmed: 25477265
Br J Haematol. 2006 Jul;134(1):116-9
pubmed: 16803577
Talanta. 2018 Jun 1;183:216-222
pubmed: 29567167
Haematologica. 1994 Sep-Oct;79(5):406-12
pubmed: 7843626
Clin Hemorheol Microcirc. 2018;69(1-2):207-214
pubmed: 29630544
Clin Hemorheol Microcirc. 2009;42(2):75-97
pubmed: 19433882
Clin Hemorheol Microcirc. 2006;35(1-2):311-6
pubmed: 16899950
Blood Rev. 2012 Apr;26 Suppl 1:S20-3
pubmed: 22631037
Thromb Res. 2016 Aug;144:119-22
pubmed: 27322087
Haematologia (Budap). 2001;31(3):237-44
pubmed: 11855786
Br J Haematol. 2011 Mar;152(5):512-23
pubmed: 21250971
Acta Haematol. 2002;108(3):144-9
pubmed: 12373086
Lancet. 2018 Jan 13;391(10116):155-167
pubmed: 28774421
Ann Hematol. 2001 Oct;80(10):577-83
pubmed: 11732868
Haematologica. 2015 Jun;100(6):730-9
pubmed: 25769545
Mediterr J Hematol Infect Dis. 2013 Jun 05;5(1):e2013044
pubmed: 23795282
Ann N Y Acad Sci. 2010 Aug;1202:231-6
pubmed: 20712798
J Pediatr Endocrinol Metab. 2016 Aug 1;29(8):953-8
pubmed: 27235671
J Am Heart Assoc. 2022 Nov;11(21):e024374
pubmed: 36314488
Clin Chim Acta. 2015 Jan 15;439:50-7
pubmed: 25314938
Thromb Res. 2012 Nov;130(5):695-702
pubmed: 22857801
Clin Exp Med. 2016 Aug;16(3):345-50
pubmed: 26052040
Ann N Y Acad Sci. 2016 Mar;1368(1):82-94
pubmed: 27186941
Thromb Haemost. 2001 Feb;85(2):204-6
pubmed: 11246533
Immunopharmacol Immunotoxicol. 2014 Aug;36(4):271-4
pubmed: 24945737
Hematol Oncol Clin North Am. 2018 Apr;32(2):223-236
pubmed: 29458728
Nucleic Acids Res. 2014 Jan;42(Database issue):D1063-9
pubmed: 24137000
Haematologica. 1995 Sep-Oct;80(5):431-3
pubmed: 8566884
J Blood Med. 2015 Jun 17;6:197-209
pubmed: 26124688
Front Mol Biosci. 2019 Dec 04;6:142
pubmed: 31867341
Mediterr J Hematol Infect Dis. 2009 Dec 29;1(1):e2009029
pubmed: 21415997
Clin Respir J. 2016 Mar;10(2):153-62
pubmed: 25069394
Ann N Y Acad Sci. 2004 Dec;1030:196-201
pubmed: 15659798
Am J Hypertens. 2006 Sep;19(9):970-7; discussion 978
pubmed: 16942942
Blood Rev. 2012 Apr;26 Suppl 1:S24-7
pubmed: 22631038
Blood. 1993 May 1;81(9):2252-6
pubmed: 8481507
J Thromb Haemost. 2010 Jan;8(1):54-9
pubmed: 19817994
Acta Haematol. 2010;124(4):191-6
pubmed: 21042009
Vox Sang. 2015 Jan;108(1):1-10
pubmed: 25286743
Int J Cardiol. 2005 Oct 20;105(1):80-4
pubmed: 16207549
Blood Cells Mol Dis. 2009 Nov-Dec;43(3):230-4
pubmed: 19654073
Int J Cardiol. 2004 Mar;94(1):25-9
pubmed: 14996470
Talanta. 2016 Oct 1;159:425-432
pubmed: 27474327
Iran J Ped Hematol Oncol. 2013;3(2):59-63
pubmed: 24575271
Hematol Oncol Clin North Am. 2018 Apr;32(2):237-245
pubmed: 29458729
Thromb Haemost. 2006 Oct;96(4):488-91
pubmed: 17003927
Ann Hematol. 2020 Oct;99(10):2265-2277
pubmed: 32803313